Sciencast Management LP Purchases 2,391 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sciencast Management LP boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 35.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 9,131 shares of the medical equipment provider’s stock after acquiring an additional 2,391 shares during the period. Sciencast Management LP’s holdings in Zimmer Biomet were worth $965,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Roman Butler Fullerton & Co. bought a new stake in Zimmer Biomet in the 4th quarter valued at about $473,000. Geode Capital Management LLC raised its stake in Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after acquiring an additional 125,852 shares during the period. M&T Bank Corp raised its stake in Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock valued at $2,884,000 after acquiring an additional 8,709 shares during the period. KLCM Advisors Inc. bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $7,825,000. Finally, Peddock Capital Advisors LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $654,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $110.79 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a market cap of $22.05 billion, a PE ratio of 24.90, a P/E/G ratio of 1.95 and a beta of 1.04. The business has a 50 day moving average of $106.74 and a 200 day moving average of $106.86. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm earned $2.20 earnings per share. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Analyst Upgrades and Downgrades

ZBH has been the topic of several analyst reports. Raymond James decreased their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada decreased their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JMP Securities reiterated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Stifel Nicolaus upped their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $124.15.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.